Evidence-Based Summary
CJC-1295 and AOD-9604 both stem from growth hormone science, but they operate through completely different biochemical strategies. CJC-1295 is an upstream secretagogue, a synthetic analogue of growth hormone-releasing hormone (GHRH) modified with the Drug Affinity Complex (DAC) to bind serum albumin. It acts directly on pituitary somatotrophs to stimulate endogenous secretion of the full 191-amino-acid native GH molecule, which in turn elevates systemic IGF-1, promotes muscle protein synthesis, and mobilizes body fat. In contrast, AOD-9604 is a synthetic 16-amino-acid cyclic peptide replicating the isolated C-terminal lipolytic domain of human growth hormone (hGH amino acids 177–191, with an added tyrosine at the N-terminus). Developed by Australian researchers in the late 1990s, AOD-9604 was hypothesized to trigger direct beta-3 adrenergic and adipocyte lipolysis while eliminating the diabetogenic (insulin-antagonistic) and proliferative (IGF-1 elevating) side effects of intact GH. However, both compounds failed clinical drug development: CJC-1295 Phase 2 trials were halted in 2006 following a fatal cardiac event, and AOD-9604 was abandoned after large Phase 2b human trials failed to demonstrate statistically significant weight loss over placebo. Neither substance is approved by the FDA or EMA, and both are explicitly prohibited in athletic competition by WADA under Section S2.
Quick Comparison: CJC-1295 vs AOD-9604
A high-level comparison of molecule class, molecular receptor targets, FDA regulatory approvals, and verified clinical programs.
| Feature | CJC-1295 | AOD-9604 |
|---|---|---|
| Primary classification | Synthetic GHRH secretagogue analogue | Synthetic C-terminal hGH peptide fragment |
| Biological target | Pituitary somatotroph GHRH receptor | Adipocyte lipolytic pathways (Putative beta-3 AR) |
| Systemic GH & IGF-1 elevation | Yes (Systemic elevation) | No (Engineered specifically to avoid IGF-1 elevation) |
| Peptide sequence length | 29 amino acids + DAC linker | 16 amino acids (Tyr-hGH[177-191]) |
| Elimination half-life | ~6 to 8 days (with DAC) | ~3 minutes (Rapid systemic clearance) |
| FDA regulatory status | Unapproved experimental chemical | Unapproved (formerly FDA Category 2; now “nominated but withdrawn”) |
| Human weight loss efficacy | Not demonstrated in controlled Phase 3 trials | Failed to show significant weight loss in Phase 2b RCT |
| WADA Prohibited status | Prohibited at all times (Section S2) | Prohibited at all times (Section S2: Peptide Fragments) |
Upstream Secretagogue vs Isolated Downstream Fragment
Why whole-axis GH elevation behaves differently from an isolated structural fragment.
CJC-1295: Pituitary Axis GHRH Agonism
Primary Target: Growth Hormone-Releasing Hormone Receptor (GHRHR)
Affinity Profile: Persistent receptor stimulation via albumin anchoring
CJC-1295 binds to pituitary somatotroph GHRHR, activating adenylate cyclase and cAMP to release full intact 22 kDa growth hormone. The resulting systemic GH spike acts on hepatic GH receptors to synthesize IGF-1 and on peripheral adipocytes to stimulate hormone-sensitive lipase (HSL).
AOD-9604: Putative Non-IGF-1 Lipolytic Fragment
Primary Targets: Proposed beta-3 adrenergic receptor cross-reactivity
Affinity Profile: Does not bind growth hormone receptor (GHR)
AOD-9604 isolates the C-terminal disulfide loop of hGH (Cys182-Cys189). In rodent adipocytes, it upregulates beta-3 adrenergic receptor expression and stimulates lipolysis while inhibiting lipogenesis. Because it lacks the N-terminal functional binding domain, it does not activate GHR, does not stimulate IGF-1, and does not alter systemic insulin sensitivity.
Clinical Trial Failures & Compounding Prohibitions
Both substances have been flagged by health authorities and sports integrity agencies.
CJC-1295 Status & Formulations
Not approved by the FDA or EMA for human clinical use.
AOD-9604 Status & Formulations
Not approved by the FDA or EMA for human clinical use.
Critical Regulatory Distinction
FDA previously placed AOD-9604 and CJC-1295 in Category 2 of its interim compounding policy, citing possible immunogenicity, impurity concerns and limited safety data; both now appear on FDA’s list as “nominated but withdrawn”, which is not a safety clearance. CJC-1295 clinical development was discontinued in 2006.
Phase 2 Clinical Trial Results
Both compounds entered human randomized trials before development was terminated.
CJC-1295: CJC-1295 Clinical Results
In Phase 1/2 trials, CJC-1295 DAC elevated mean GH levels by 2- to 10-fold and sustained elevated IGF-1 for up to two weeks per injection. Development was terminated after a patient in a Phase 2 trial died from a coronary event.
AOD-9604: AOD-9604 Phase 2b Obesity Trial
In a 24-week randomized, double-blind, placebo-controlled Phase 2b trial in 536 obese patients conducted by Metabolic Pharmaceuticals (2007), AOD-9604 failed to demonstrate statistically significant weight loss compared to placebo, leading the company to abandon development for obesity.
Documented Side Effects & Unknowns
Both substances lack long-term human safety validation.
| Safety Consideration | CJC-1295 | AOD-9604 |
|---|---|---|
| Cardiovascular safety | Phase 2 trial halted after fatal coronary event | Generally well tolerated in Phase 2 trials, but efficacy was absent |
| Carbohydrate metabolism | Increases fasting blood glucose via sustained GH | Does not alter blood glucose or insulin sensitivity in trials |
| Injection-site reactions | Erythema, induration, sustained pain | Mild, transient local reactions |
What CJC-1295 and AOD-9604 Have in Common
Where the two compounds overlap in biology, evidence or regulatory context.
Growth Hormone Scientific Origin
Both peptides were developed to harness the lipolytic and metabolic benefits of growth hormone.
Unapproved Experimental Status
Neither compound holds approval from the FDA or EMA, and both are banned by WADA under Section S2.
Key Scientific & Clinical Differences
Meaningful distinctions in mechanism, strength of evidence, safety and regulatory status.
IGF-1 Stimulation
CJC-1295 substantially elevates systemic IGF-1; AOD-9604 does not stimulate IGF-1.
Mechanism of Action
CJC-1295 stimulates the pituitary gland to release endogenous GH; AOD-9604 is an isolated fragment acting directly on fat cells.
Elimination Half-Life
CJC-1295 DAC persists for 6–8 days; AOD-9604 clears from circulation within minutes.
Scientific Comparison vs Clinical Recommendations
Inside Peptides compares scientific evidence, receptor pharmacology, and official regulatory documents to advance public and professional understanding. We do not determine which compound is appropriate for an individual patient, rank medications with arbitrary scores, or recommend initiating or switching treatments.
Decisions about any medicine require a licensed healthcare professional who can weigh personal medical history, contraindications, interactions and monitoring needs. Unapproved peptides have no established safe use, and products sold as “research chemicals” are not the preparations studied in clinical research.
Approved Uses vs Online Claims
A critical scientific distinction between verified, FDA-approved clinical uses and unverified claims circulating on social media and vendor platforms.
AOD-9604 is an FDA-approved fat burner that melts belly fat with zero side effects
insufficientAOD-9604 is NOT FDA-approved and failed human Phase 2b obesity trials.
In a 536-patient clinical trial, AOD-9604 failed to outperform placebo for weight loss. The FDA has actively warned compounding pharmacies against marketing it.
Evidence Strength Across Clinical Domains
Inside Peptides evaluates scientific certainty at the claim level. Because clinical evidence varies significantly depending on the therapeutic endpoint evaluated, each domain is assessed independently.
Systemic GH/IGF-1 Elevation
CJC-1295 consistently raises GH/IGF-1; AOD-9604 does not elevate these markers.
Human Weight Loss
Neither peptide is proven to cause clinically significant fat reduction in Phase 3 RCTs.
What Research Still Doesn’t Tell Us
Identifying open scientific questions, pending active-comparator trials, and areas where long-term clinical data remain incomplete.
AOD-9604 Cartilage Repair Hypothesis
Investigating whether AOD-9604 provides any intra-articular benefits in preclinical osteoarthritis models, independent of its failed obesity indication.
Related Compound Profiles
Individual profiles provide full molecular datasheets, CAS numbers, preclinical histories, and compound monographs.
Related Educational Resources
Scientific & Regulatory References
Every pharmacological mechanism, clinical trial result, and regulatory approval cited on this page is traceable to official FDA prescribing documentation, ClinicalTrials.gov registries, or peer-reviewed medical publications.
-
Clinical Trial Report
Results of the Phase 2B clinical trial of AOD9604 in obesity
-
Peer-Reviewed Article
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295